Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma

The deletion of 12p (del(12p)) has been described as a novel negative prognostic marker in multiple myeloma (MM) and has gained increasing attention in recent years. However, its impact on MM is still controversial. In this study, we comprehensively evaluated the clinical impact of 12p13 deletion us...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Li, Fei, Xu, Yan, Deng, Ping, Yang, Ye, Sui, Weiwei, Jin, Fengyan, Hao, Mu, Li, Zengjun, Zang, Meirong, Zhou, Dehui, Gu, Zhimin, Ru, Kun, Wang, Jianxiang, Cheng, Tao, Qiu, Lugui
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4496228/
https://ncbi.nlm.nih.gov/pubmed/25831238
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars